Ovarian Cancer

Drug Name: Elahere Active Ingredient: mirvetuximab soravtansine-gynx Indications: To treat patients with recurrent ovarian cancer that is resistant to platinum therapy Approval Date: 11/14/2022 Company: ImmunoGen, Inc Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf